GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » hVIVO PLC (LSE:HVO) » Definitions » Total Liabilities

hVIVO (LSE:HVO) Total Liabilities : £48.90 Mil (As of Dec. 2023)


View and export this data going back to 2012. Start your Free Trial

What is hVIVO Total Liabilities?

hVIVO's Total Liabilities for the quarter that ended in Dec. 2023 was £48.90 Mil.

hVIVO's quarterly Total Liabilities declined from Dec. 2022 (£31.16 Mil) to Jun. 2023 (£29.93 Mil) but then increased from Jun. 2023 (£29.93 Mil) to Dec. 2023 (£48.90 Mil).

hVIVO's annual Total Liabilities increased from Dec. 2021 (£21.59 Mil) to Dec. 2022 (£31.16 Mil) and increased from Dec. 2022 (£31.16 Mil) to Dec. 2023 (£48.90 Mil).


hVIVO Total Liabilities Historical Data

The historical data trend for hVIVO's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

hVIVO Total Liabilities Chart

hVIVO Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.19 26.25 21.59 31.16 48.90

hVIVO Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.59 26.04 31.16 29.93 48.90

hVIVO Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

hVIVO's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=35.18+(12.163+1.559
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=48.90

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=83.228-34.326
=48.90

hVIVO's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=35.18+(12.163+1.559
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=48.90

Total Liabilities=Total Assets (Q: Dec. 2023 )-Total Equity (Q: Dec. 2023 )
=83.228-34.326
=48.90

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


hVIVO Total Liabilities Related Terms

Thank you for viewing the detailed overview of hVIVO's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


hVIVO (LSE:HVO) Business Description

Traded in Other Exchanges
Address
42, New Road, Queen Mary Bioenterprises Innovation Centre, London, GBR, E1 2AX
hVIVO PLC is a European-focused, rare, and orphan drug consulting services platform. The principal activity of the Group is that of a rapidly growing specialist CRO pharmaceutical services company, which involves the testing of vaccines and antivirals using human-challenge clinical trials. The group is also engaged in Venn Life Sciences' Clinical Research Division, providing a suite of consulting and clinical trial services to pharmaceutical, biotechnology, and medical device organizations.

hVIVO (LSE:HVO) Headlines

No Headlines